Extraction of interoperable data from healthcare documents by identifying Common Data Elements: an analysis of Radiation Therapy Planning CT Physician Order Entry records
CONCLUSION: Structured and interoperable documentation of medical information can be achieved using common data elements. Our analysis showed that a lot of information recorded with healthcare documents can be presented with this approach. Yet, in the analyzed cohort of planning CT order entries, only a few common data elements were shared among the majority of documents. A common vocabulary and consensus upon relevant information is required to promote interoperability and standardization.PMID:37729894 | DOI:10.1159/000534204 (Source: Oncology)
Source: Oncology - September 20, 2023 Category: Cancer & Oncology Authors: Fabio Dennst ädt Paul Martin Putora Michael Heuser Eugenia Vlaskou Badra Brigitta Gertrud Baumert Dominic Leiser Nikola Cihoric Source Type: research
Outcomes of patients with Child-Pugh B and unresectable hepatocellular carcinoma undergoing first-line systemic treatment with sorafenib, lenvatinib, or atezolizumab plus bevacizumab
CONCLUSION: Determining the hepatic reserve of patients with unresectable HCC might be useful for identifying patents suitable for systemic treatment for HCC. Atezo + Bev might prolong the PFS of patients with a Child-Pugh score of 7.PMID:37729889 | DOI:10.1159/000533859 (Source: Oncology)
Source: Oncology - September 20, 2023 Category: Cancer & Oncology Authors: Chihiro Kikugawa Shinsuke Uchikawa Tomokazu Kawaoka Takahiro Kinami Shigeki Yano Kei Amioka Kensuke Naruto Yuwa Ando Kenji Yamaoka Masataka Tsuge Yumi Kosaka Kazuki Ohya Nami Mori Shintaro Takaki Keiji Tsuji Hirotaka Kouno Hiroshi Kohno Kei Morio Takashi Source Type: research
Extraction of interoperable data from healthcare documents by identifying Common Data Elements: an analysis of Radiation Therapy Planning CT Physician Order Entry records
CONCLUSION: Structured and interoperable documentation of medical information can be achieved using common data elements. Our analysis showed that a lot of information recorded with healthcare documents can be presented with this approach. Yet, in the analyzed cohort of planning CT order entries, only a few common data elements were shared among the majority of documents. A common vocabulary and consensus upon relevant information is required to promote interoperability and standardization.PMID:37729894 | DOI:10.1159/000534204 (Source: Oncology)
Source: Oncology - September 20, 2023 Category: Cancer & Oncology Authors: Fabio Dennst ädt Paul Martin Putora Michael Heuser Eugenia Vlaskou Badra Brigitta Gertrud Baumert Dominic Leiser Nikola Cihoric Source Type: research
Clinical implication of CDH1 mutations in genetic testing for diffuse gastric cancer patients
CONCLUSIONS: We conclude that germline CDH1 genetic testing is indicated only in families meeting the clinical criteria for the HDGC syndrome. This observation suggests that clinical phenotypes that do not clearly fulfill these criteria should not be considered for CDH1 genetic testing.PMID:37725907 | DOI:10.1159/000533774 (Source: Oncology)
Source: Oncology - September 19, 2023 Category: Cancer & Oncology Authors: Giovanni Corso Cristina Maria Trovato Salvatore Petitto Antonia Girardi Alessandra Margherita De Scalzi Beatrice Bianchi Francesca Magnoni Antonio Cioffi Viviana Galimberti Paolo Veronesi Giovanni Mazzarol Patrick Maisonneuve Source Type: research
Clinical utility of inflammatory and nutritious index as therapeutic prediction of nivolumab plus ipilimumab in advanced NSCLC
CONCLUSION: The NLR, PLR, SII, PNI, ALI, and GPS were significantly associated with the outcome of Nivo-Ipi treatment in patients with NSCLC. The PNI was the most suitable marker regardless of histological type. The SII and PNI were the most promising markers for patients with and without PD-L1 expression, respectively.PMID:37725914 | DOI:10.1159/000534169 (Source: Oncology)
Source: Oncology - September 19, 2023 Category: Cancer & Oncology Authors: Ou Yamaguchi Kyoichi Kaira Hisao Imai Atsuto Mouri Ayako Shiono Yu Miura Kosuke Hashimoto Kunihiko Kobayashi Hiroshi Kagamu Source Type: research
Clinical implication of CDH1 mutations in genetic testing for diffuse gastric cancer patients
CONCLUSIONS: We conclude that germline CDH1 genetic testing is indicated only in families meeting the clinical criteria for the HDGC syndrome. This observation suggests that clinical phenotypes that do not clearly fulfill these criteria should not be considered for CDH1 genetic testing.PMID:37725907 | DOI:10.1159/000533774 (Source: Oncology)
Source: Oncology - September 19, 2023 Category: Cancer & Oncology Authors: Giovanni Corso Cristina Maria Trovato Salvatore Petitto Antonia Girardi Alessandra Margherita De Scalzi Beatrice Bianchi Francesca Magnoni Antonio Cioffi Viviana Galimberti Paolo Veronesi Giovanni Mazzarol Patrick Maisonneuve Source Type: research
Clinical utility of inflammatory and nutritious index as therapeutic prediction of nivolumab plus ipilimumab in advanced NSCLC
CONCLUSION: The NLR, PLR, SII, PNI, ALI, and GPS were significantly associated with the outcome of Nivo-Ipi treatment in patients with NSCLC. The PNI was the most suitable marker regardless of histological type. The SII and PNI were the most promising markers for patients with and without PD-L1 expression, respectively.PMID:37725914 | DOI:10.1159/000534169 (Source: Oncology)
Source: Oncology - September 19, 2023 Category: Cancer & Oncology Authors: Ou Yamaguchi Kyoichi Kaira Hisao Imai Atsuto Mouri Ayako Shiono Yu Miura Kosuke Hashimoto Kunihiko Kobayashi Hiroshi Kagamu Source Type: research
Neoadjuvant triplet chemotherapy with docetaxel, cisplatin plus 5-FU vs docetaxel, cisplatin plus S-1 for advanced esophageal squamous cell carcinoma: Propensity score matched analysis
CONCLUSIONS: Neoadjuvant DCS therapy for resectable advanced ESCC did not result in significantly higher clinical and pathological response than neoadjuvant DCF therapy. However, neoadjuvant DCS therapy for resectable ESCC required comparatively shorter hospital stays and incurred lower costs, making it an attractive therapeutic option.PMID:37708864 | DOI:10.1159/000533790 (Source: Oncology)
Source: Oncology - September 14, 2023 Category: Cancer & Oncology Authors: Junya Kitadani Toshiyasu Ojima Keiji Hayata Taro Goda Akihiro Takeuchi Shinta Tominaga Naoki Fukuda Tomoki Nakai Hiroki Yamaue Manabu Kawai Source Type: research
Antibiotics may interfere with nivolumab efficacy in patients with head and neck squamous cell carcinoma
CONCLUSION: Our findings indicate that antibiotic treatment significantly shortens the PFS with nivolumab therapy in patients with head and neck SCC.PMID:37708868 | DOI:10.1159/000533860 (Source: Oncology)
Source: Oncology - September 14, 2023 Category: Cancer & Oncology Authors: Reio Ueta Hiroo Imai Ken Saijo Yoshifumi Kawamura Shuto Kodera Keigo Komine Kota Ouchi Yuki Kasahara Sakura Taniguchi Yuya Yoshida Keiju Sasaki Hidekazu Shirota Masanobu Takahashi Chikashi Ishioka Source Type: research
Neoadjuvant triplet chemotherapy with docetaxel, cisplatin plus 5-FU vs docetaxel, cisplatin plus S-1 for advanced esophageal squamous cell carcinoma: Propensity score matched analysis
CONCLUSIONS: Neoadjuvant DCS therapy for resectable advanced ESCC did not result in significantly higher clinical and pathological response than neoadjuvant DCF therapy. However, neoadjuvant DCS therapy for resectable ESCC required comparatively shorter hospital stays and incurred lower costs, making it an attractive therapeutic option.PMID:37708864 | DOI:10.1159/000533790 (Source: Oncology)
Source: Oncology - September 14, 2023 Category: Cancer & Oncology Authors: Junya Kitadani Toshiyasu Ojima Keiji Hayata Taro Goda Akihiro Takeuchi Shinta Tominaga Naoki Fukuda Tomoki Nakai Hiroki Yamaue Manabu Kawai Source Type: research
Antibiotics may interfere with nivolumab efficacy in patients with head and neck squamous cell carcinoma
CONCLUSION: Our findings indicate that antibiotic treatment significantly shortens the PFS with nivolumab therapy in patients with head and neck SCC.PMID:37708868 | DOI:10.1159/000533860 (Source: Oncology)
Source: Oncology - September 14, 2023 Category: Cancer & Oncology Authors: Reio Ueta Hiroo Imai Ken Saijo Yoshifumi Kawamura Shuto Kodera Keigo Komine Kota Ouchi Yuki Kasahara Sakura Taniguchi Yuya Yoshida Keiju Sasaki Hidekazu Shirota Masanobu Takahashi Chikashi Ishioka Source Type: research
Neoadjuvant triplet chemotherapy with docetaxel, cisplatin plus 5-FU vs docetaxel, cisplatin plus S-1 for advanced esophageal squamous cell carcinoma: Propensity score matched analysis
CONCLUSIONS: Neoadjuvant DCS therapy for resectable advanced ESCC did not result in significantly higher clinical and pathological response than neoadjuvant DCF therapy. However, neoadjuvant DCS therapy for resectable ESCC required comparatively shorter hospital stays and incurred lower costs, making it an attractive therapeutic option.PMID:37708864 | DOI:10.1159/000533790 (Source: Oncology)
Source: Oncology - September 14, 2023 Category: Cancer & Oncology Authors: Junya Kitadani Toshiyasu Ojima Keiji Hayata Taro Goda Akihiro Takeuchi Shinta Tominaga Naoki Fukuda Tomoki Nakai Hiroki Yamaue Manabu Kawai Source Type: research
Antibiotics may interfere with nivolumab efficacy in patients with head and neck squamous cell carcinoma
CONCLUSION: Our findings indicate that antibiotic treatment significantly shortens the PFS with nivolumab therapy in patients with head and neck SCC.PMID:37708868 | DOI:10.1159/000533860 (Source: Oncology)
Source: Oncology - September 14, 2023 Category: Cancer & Oncology Authors: Reio Ueta Hiroo Imai Ken Saijo Yoshifumi Kawamura Shuto Kodera Keigo Komine Kota Ouchi Yuki Kasahara Sakura Taniguchi Yuya Yoshida Keiju Sasaki Hidekazu Shirota Masanobu Takahashi Chikashi Ishioka Source Type: research
Neoadjuvant triplet chemotherapy with docetaxel, cisplatin plus 5-FU vs docetaxel, cisplatin plus S-1 for advanced esophageal squamous cell carcinoma: Propensity score matched analysis
CONCLUSIONS: Neoadjuvant DCS therapy for resectable advanced ESCC did not result in significantly higher clinical and pathological response than neoadjuvant DCF therapy. However, neoadjuvant DCS therapy for resectable ESCC required comparatively shorter hospital stays and incurred lower costs, making it an attractive therapeutic option.PMID:37708864 | DOI:10.1159/000533790 (Source: Oncology)
Source: Oncology - September 14, 2023 Category: Cancer & Oncology Authors: Junya Kitadani Toshiyasu Ojima Keiji Hayata Taro Goda Akihiro Takeuchi Shinta Tominaga Naoki Fukuda Tomoki Nakai Hiroki Yamaue Manabu Kawai Source Type: research
Antibiotics may interfere with nivolumab efficacy in patients with head and neck squamous cell carcinoma
CONCLUSION: Our findings indicate that antibiotic treatment significantly shortens the PFS with nivolumab therapy in patients with head and neck SCC.PMID:37708868 | DOI:10.1159/000533860 (Source: Oncology)
Source: Oncology - September 14, 2023 Category: Cancer & Oncology Authors: Reio Ueta Hiroo Imai Ken Saijo Yoshifumi Kawamura Shuto Kodera Keigo Komine Kota Ouchi Yuki Kasahara Sakura Taniguchi Yuya Yoshida Keiju Sasaki Hidekazu Shirota Masanobu Takahashi Chikashi Ishioka Source Type: research
